New hope for Tough-to-Treat breast cancer: major trial launches
NCT ID NCT07461454
Summary
This study is testing a new drug called YL202 for people with a specific type of advanced breast cancer that has stopped responding to chemotherapy. It will compare YL202 against several standard treatment options to see which is better at controlling the cancer and helping patients live longer. The goal is to find a more effective treatment for this difficult stage of the disease.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED OR METASTATIC BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Fudan University Shanghai Cancer Center
Shanghai, Shanghai Municipality, 201321, China
Contact
Conditions
Explore the condition pages connected to this study.